Funder: NIH National Institute on Drug Abuse (NIDA)

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohort studies that addresses the intersection of HIV and substance use. This program is a multidisciplinary platform to support basic, epidemiologic, and clinical research on HIV and HIV-associated co-morbidities and co-infections among populations with substance use and substance use disorders (SUDs) and to address research questions at the individual and population level. The purpose of this notice of funding opportunity (NOFO) is to support the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance use in alignment with NIH-HIV research priorities in order to inform policy or practice. Cohort sites supported under this program are required to report to and collaborate with a NIDA funded Coordinating Center, including participating in research agendas addressing NIDA’s high priority areas. 

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Topics: Clinical Presentation of Infection, ARDS, Cellular / Molecular Response, Inflammation, Long-term Impact of Infection, Pneumonia, Sensory, Clinical Trial, Co-Morbidities, Immune Disorders, HIV, Immunosuppression, Inflammation, Substance Abuse, Community Engagement, Epidemiology, Clinical History, Clinical Outcome, Contact Tracing, Incidence, Risk Factors, Surveillance, Transmission, Health Disparities, Healthcare Implementation, Immunity, Immunology, Host Factors, Host Response, Prevention, Social Distancing, Vaccine Development, Vaccine Efficacy, Vaccines, Vaccine Hesitancy, Social Determinants of Health, Treatments, Immunological Response Targets, Treatment Efficacy, Treatment Reliability, Treatment Scalability, Drugs, Antibody-based Treatment, Drug Development, Drug Repurposing, Drug Targets, Immunological Response Targets, Anti-viral Targets